Capecitabine , ≥99% , 154361-50-9

Synonym(s):
5′-Deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine;CAP;Capecitabine;Ro-9-1978

CAS NO.：154361-50-9

Empirical Formula: C15H22FN3O6

Molecular Weight: 359.35

MDL number: MFCD00930626

EINECS: 604-948-1

PRODUCT Properties

• Melting point: 110-121°C
• Density: 1.49±0.1 g/cm3(Predicted)
• Flash point: 87℃
• storage temp.: 2-8°C
• solubility: H2O: soluble10mg/mL, clear (warmed)
• pka: 5.41±0.40(Predicted)
• form: powder
• color: white to beige
• Merck: 14,1754
• InChIKey: GAGWJHPBXLXJQN-UORFTKCHSA-N
• SMILES: C[C@H]1O[C@@H](N2C=C(F)C(NC(OCCCCC)=O)=NC2=O)[C@H](O)[C@@H]1O

Description and Uses

Capecitabine is a new oral fluoropyrimidine carbamate for patients with advanced neoplastic disease, approved as Xeloda for the treatment of refractory metastatic breast cancer after failure on Paclitaxel and an anthracycline-based chemotherapy regimen ; it is a prodrug of doxifluridine (5-fluorouracil ; 5-FU) activated by a cascade of 3 enzymes concentrated in human liver and cancer tissue, resulting in the selective release of 5-FU at the tumor site and offering a prolonged tumour exposure to 5-FU. Oral Capecitabine passes intact through the intestinal mucosa, is converted first by carboxylesterase to 5'-deoxy-5- fluorocytidine in the liver, then by cytidine deaminase to 5'-deoxy-5-fluorouridine in the liver and tumour tissues and finally by thymidine phosphorylase to 5-FU in tumors. Therefore, Xeloda is much safer and more effective than 5-FU (for example, in the HCT116 human colon cancer and the MX-1 breast cancer xenograft .models).

An antiproliferative 5-fluorouracil releasing compound

Safety

• Symbol(GHS): GHS08
• Signal word: Danger
• Hazard statements: H341-H350-H360FD
• Precautionary statements: P201-P308+P313
• Hazard Codes: T
• Risk Statements: 45-60-61-68
• Safety Statements: 53-22-36/37-45
• WGK Germany: 3
• RTECS: HA3852500
• HS Code: 29349990